NASDAQ$SGMO
Sangamo Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported business highlights and third quarter 2020 financial results.
Sangamo Therapeutics reported a decrease in net loss attributable to Sangamo for the third quarter ended September 30, 2020, with revenues increasing compared to the same period in 2019. The company also highlighted clinical execution momentum across its portfolio and the completion of research activities in its ALS program partnered with Pfizer.
- Earned a $30 million milestone from Pfizer for the dosing of the first patient in the registrational Phase 3 AFFINE study of investigational hemophilia A gene therapy giroctocogene fitelparvovec (SB-525).
- Pfizer provided updated data from the Phase 1/2 Alta study of giroctocogene fitelparvovec demonstrating tolerability, clinically meaningful factor levels with no bleeds and no prophylactic factor use through up to 85 weeks in the longest patient treated in the highest dose cohort.
- Completed dosing of the first two patients in the Phase 1/2 STAAR study evaluating our investigational ST-920 gene therapy in Fabry disease.
- Completed research activities in our collaboration with Pfizer to develop gene regulation therapies using zinc finger protein transcription factors for the treatment of C9ORF72-related Amyotrophic Lateral Sclerosis (ALS).
Headline financials
Revenue & EPS history
Sangamo · Revenue · Quarterly
$57.8M
Forward guidance
Revised full year operating expense guidance was initially provided on February 28, 2020 and revised on August 5, 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2020
+0.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
-3.2%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+59.1%
Q1 2017
Best reaction
-39.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.3% | -12.0% | — | |
| Q1 2026 | +3.4% | -5.0% | +10.4% | |
| Q3 2025 | -16.1% | -9.1% | -9.1% | |
| Q2 2025 | -5.6% | +12.5% | +14.6% | |
| Q1 2025 | -39.1% | -37.3% | -33.3% | |
| Q4 2024 | -16.2% | -13.9% | -29.7% | |
| Q3 2024 | -9.6% | -24.1% | -29.3% | |
| Q2 2024 | +11.6% | +32.5% | -2.6% | |
| Q1 2024 | +11.7% | +14.0% | +14.0% | |
| Q4 2023 | -9.4% | -1.2% | -37.2% | |
| Q3 2023 | -27.0% | -30.2% | -28.6% | |
| Q2 2023 | -10.3% | -7.7% | -18.8% | |
| Q1 2023 | -0.6% | -6.2% | -21.7% | |
| Q4 2022 | +2.8% | +4.2% | -41.5% | |
| Q3 2022 | -15.0% | -19.0% | -14.3% | |
| Q2 2022 | +8.3% | +9.2% | +15.2% | |
| Q1 2022 | -9.6% | -15.5% | -18.8% | |
| Q4 2021 | +9.7% | +9.3% | +6.9% | |
| Q3 2021 | +20.0% | +14.2% | -11.4% | |
| Q2 2021 | +3.2% | +7.0% | +6.6% | |
| Q1 2021 | -10.7% | -9.4% | -7.4% | |
| Q4 2020 | -9.2% | -2.8% | -2.7% | |
| Q3 2020 | +12.6% | +8.7% | -6.2% | |
| Q2 2020 | +2.4% | +9.1% | -12.3% | |
| Q1 2020 | +12.5% | +15.4% | +27.1% | |
| Q4 2019 | +27.5% | +21.9% | -4.9% | |
| Q3 2019 | -1.3% | +3.4% | +23.3% | |
| Q2 2019 | +1.1% | -5.2% | -10.3% | |
| Q1 2019 | -14.8% | -13.5% | -15.6% | |
| Q4 2018 | +7.8% | +8.2% | +2.4% | |
| Q3 2018 | -22.0% | -24.5% | -20.9% | |
| Q2 2018 | +8.9% | +13.2% | -2.1% | |
| Q1 2018 | -5.8% | -5.5% | +1.2% | |
| Q4 2017 | +12.4% | +5.6% | -2.0% | |
| Q3 2017 | +12.6% | +7.9% | +41.4% | |
| Q2 2017 | +9.2% | +33.3% | +54.6% | |
| Q1 2017 | +59.1% | +90.9% | +65.9% | |
| Q4 2016 | +9.3% | +10.5% | +9.3% | |
| Q3 2016 | +2.7% | -2.7% | -4.1% | |
| Q2 2016 | -26.0% | -26.9% | -34.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -11.7% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | -17.4% | — | — | |
| Q1 2015 | +7.9% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2014 | +1.4% | — | — | |
| Q2 2014 | +4.4% | — | — | |
| Q1 2014 | -9.4% | — | — | |
| Q4 2013 | +3.5% | — | — | |
| Q3 2013 | +4.6% | — | — | |
| Q2 2013 | +2.9% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -2.6% | — | — | |
| Q2 2012 | -0.8% | — | — | |
| Q1 2012 | +5.1% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +2.7% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q3 2010 | +2.9% | — | — | |
| Q2 2010 | -1.8% | — | — | |
| Q1 2010 | -12.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro